Canine mammary tumours (CMTs) are one of the most common malignancies in bitches. Platelet-derived growth factor receptor (PDGFR) α and β, vascular endothelial growth factor receptor-2 (VEGFR-2) and CD117 are tyrosine kinase receptors involved in several tumours and represent suitable targets for specific therapy with toceranib phosphate. The purpose of this study was to evaluate the expression of these receptors in the pathogenesis and progression of CMTs. PDGFRα, PDGFRβ, VEGFR-2 and CD117 were expressed in 46/83 (55.4 per cent), 33/83 (39.8 per cent), 46/83 (55.4 per cent) and 32/83 (38.5 per cent) of CMTs, respectively. Immunohistochemical results showed a statistically significant loss of PDGFRα and PDGFRβ expression in simple carcinomas compared with complex/mixed carcinomas. Protein expression by western blot revealed specific bands corresponding to PDGFRα and VEGFR-2 in 3/7 and in 1/7 cell lines. Moreover, in vitro treatment showed that toceranib phosphate weakly reduced cell proliferation in one canine mammary cell line. Before considering TKR inhibitors for possible therapeutic approaches, actually further studies are necessary to evaluate the effect of these drugs on CMTs in vivo.
Introduction
Canine mammary tumours (CMTs) are one of the most common tumours that occur in entire bitches. 1 2 According to the literature, the percentage of the malignant form varies from 40 per cent to 70 per cent, and simple carcinoma represents the most common histotype, followed by mixed and complex tumours. [3] [4] [5] The epithelial component of CMTs has been recognised as a potential model for human breast cancer due to their similar histological and clinical features. 6 7 Platelet-derived growth factor receptors (PDGFR) α and β, vascular endothelial growth factor receptor-2 (VEGFR-2) and CD117 are tyrosine kinase receptors (TKRs) that are able to activate many of the major cellular signal transduction pathways 8 and are involved in both physiological processes and tumoural diseases. 9 10 Numerous studies have demonstrated the overexpression or activation of PDGFRs, VEGFR-2 and CD117 in several canine tumours. [11] [12] [13] To the authors' knowledge, there are still no data regarding the expression of PDGFRs in CMTs, although VEGFR-2 is expressed in 58 per cent of CMTs and is statistically associated with VEGF immunoreactivity in cancer cells. 14 15 Further, CD117 is reported to be highly expressed in malignant CMTs, which suggests that it plays a role in high-grade canine mammary carcinomas (CMCs). 16 17 In human breast cancer, PDGFRs and CD117 are involved in cellular differentiation and invasion and in the tumoural microenvironment 18 ; thus, the potential use of targeted therapy has been suggested for this tumour. 19 The use of TKR inhibitors (TKIs) in human and veterinary medicine depends on the receptor expression of the specific tumour, as well as the activation and/or presence or absence of mutation of TKRs. 20 21 The TKRs evaluated in this study represent an attractive target for toceranib phosphate (Zoetis), which is a veterinary TKI that selectively inhibits VEGFR-2, PDGFRs and CD117 and is currently used for the treatment of mast cell tumours. However, there is increasing evidence that same other solid tumours such as anal sac carcinomas, head and neck, thyroid carcinomas can be successfully treated with this molecule but its use is actually off-label. [22] [23] [24] The aims of the present study are to characterise the expression of PDGFRα, PDGFRβ, VEGFR-2 and CD117 in spontaneous CMTs, to evaluate the in vitro effect of toceranib phosphate on canine carcinoma mammary cell lines and to provide information regarding TKRs as molecular targets in this tumour.
Materials and methods

Sample collection
In total, 83 spontaneous malignant CMTs, 16 benign CMTs, 7 hyperplastic mammary glands and 4 normal mammary glands were retrieved from a retrospective study at the Hospital of the Department of Veterinary Sciences of the University of Turin; the normal/hyperplastic glands were obtained during postmortem examination from female dogs with healthy mammary glands.
Histological diagnosis
Samples were fixed in 10.0 per cent buffered neutral formalin solution for at least 24 hours, embedded in paraffin wax blocks, cut into 4-μm-thick slices and stained with haematoxylin and eosin. CMTs were histologically classified according to Goldschmidt and others. 25 
Immunohistochemical analysis
Immunohistochemical (IHC) analysis was carried out on two sections of 4-µm formalin-fixed paraffin blocks. Primary antibodies employed were VEGFR-2 (Rabbit Polyclonal, Santa Cruz Biotechnology; diluted 1:150), PDGFRα (Rabbit Polyclonal, Santa Cruz Biotechnology; diluted 1:100), PDGFRβ (Rabbit Polyclonal, Santa Cruz Biotechnology; diluted 1:200), CD117 (Rabbit Polyclonal, Dako, diluted 1:400) and were detected using the avidin-biotin peroxidase complex technique with the Vectastain Elite ABC Kit (Vector Laboratories). Canine skin, prostatic carcinoma, normal spleen and mast cell tumour were used as external positive controls for PDGFRα, PDGFRβ, VEGFR-2 and CD117, respectively. For the negative controls, the previous external positive controls were incubated with normal rabbit IgG (sc-2027, St. Cruz Biotechnology). Immunolabelled slides were randomised and masked for blinded examination, which was independently performed by three PDGFR, platelet-derived growth factor receptor; VEGFR-2, vascular endothelial growth factor receptor-2.
observers (LM, SI and YM). When there was a disagreement (<5 per cent of the slides), a consensus among the three observers was reached using a multihead microscope. Cytoplasmic immunolabelling of PDGFRs and VEGFR-2 was evaluated in neoplastic and stromal cells (fibroconnective tissue within and surrounding the tumour) separately using the scoring system adopted by Donnem and others. 26 27 CD117 immunoreactivity was evaluated applying the method adopted by Brunetti and others 16 
CMC cell lines
Two canine primary (CYPp, CTB) and one metastatic (CYPm) mammary carcinoma cell lines were provided by the University of Veterinary Medicine of Tokyo, and the CF33 cell line was obtained by the American Type Culture Collection. All cell lines were cultured as previously reported.
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Establishment of Chicca, Lilly, Milly and NEM cell lines
Tissue samples from three dogs with spontaneous grade III simple carcinomas that were surgically treated (Chicca, Lilly, Milly) and from normal mammary tissue (NEM) were collected. After manual disaggregation, tissue fragments from Chicca, Lilly and Milly were digested at 37°C for 30-60 minutes in sterile PBS containing 0.25 mg/ml collagenase type IA (SigmaAldrich) and were then centrifuged and suspended in Dulbecco's modified Eagle's medium. For the 'Lilly' cell line, 10 µg/ml insulin (Sigma-Aldrich) was added. The NEM cell line was established according to the method presented in the literature, 29 and monodispersed cells were grown in Dulbecco's modified Eagle's medium/ Nutrient Mixture F12 Ham (DMEM/F12; Sigma-Aldrich) supplemented with 5% fetal calf serum, 5000 IU/ml penicillin, 5 mg/ml streptomycin, 10 µg/ml insulin, 0.5 µg/ml hydrocortisone and 10 ng/ml cholera toxin. To confirm the epithelial cells of origin, monoclonal mouse anti-cytokeratin (CK) 5 antibody (clone PCK103; isotype IgG 1 ; Euro-Diagnostica; diluted 1:10) and polyclonal rabbit anti-CK14 antibody (Covance Research; diluted 1:500) were used (data available from the authors).
Western blot analysis
Western blot (WB) analysis was carried out on the protein lysate obtained from previous normal and CMC cell lines as previously described. 30 After transferring into Hybond-C Extra membranes (American Biosciences), they were incubated with the following primary antibodies: VEGFR-2 (Rabbit Polyclonal, Santa Cruz Biotechnology; diluted 1:1000), PDGFRα (Rabbit Polyclonal, Santa Cruz Biotechnology; diluted 1:1000), PDGFRβ (Rabbit Polyclonal, Cell Signaling Technology; diluted 1:1000) and CD117 (Rabbit Polyclonal, Dako, diluted 1:1000). The membranes were then incubated with a secondary horseradish peroxidase-linked antibody and subsequently with enhanced chemiluminescence reagent (Super Signal West Pico Mouse IgG Detection Kit, Thermo Scientific).
Immunocytochemistry CMC cell lines were grown into wells of eight-well chamber slides (Nalgene) at a confluence of 50 per cent. After adhesion and medium removing, the cells were fixed in methanol for 10 minutes at room temperature and washed three times in PBS for a total of 15 minutes. After washing, the cells were incubated with primary antibodies according to the previous procedure.
Proliferation assay after in vitro inhibition with toceranib phosphate
The CYPm and CTB cell lines overexpressing PDGFRα and VEGFR-2 were selected for an in vitro test. A canine osteosarcoma cell line (Penny), expressing high levels of PDGFRs, was used as positive control.
11 First, 10,000 cells from each cell line were seeded in 96-well plates, allowed to attach overnight and treated with different concentrations of toceranib (150nM, 300nM, 600nM, 1µM, 1.5µM) diluted in dimethyl sulfoxide 10 per cent for 12, 24 and 48 hours. To measure cell proliferation and cytotoxicity, the Cell Counting Kit-8 (Enzo Life Sciences), a colorimetric semiquantitative assay kit, was used. The experiment was performed in triplicate and repeated three times.
Statistical analysis
IHC results were grouped into contingency tables and analysed using Fisher's exact test or χ 2 test. Proliferating data were analysed using Student's t-test. Data were analysed using MedCalc Statistical Software V.13.3 (MedCalc Software bvba). P<0.05 was considered statistically significant.
Results
According to the histological classification of Goldschmidt and others, 25 Tables 1 and 2 , and immunohistochemistry pictures are shown in Fig 1. As shown in Table 1 , the authors found that in malignant tumours epithelial Table 2 ). In malignant tumours, VEG-FR-2 was expressed in 46/83 (55.4 per cent) samples at the epithelial level, whereas in stromal cells it was expressed in 18/83 (21.7 per cent) samples. No statistically significant correlation was found between VEGFR-2 and histological grade. CD117 was negative in 61.4% of the cases. The positive samples were distributed as follows: 28.9 per cent (score 1), 6.1 per cent (score 2) and 3.6 per cent (score 3); no statistically significant correlation was found between CD117 and histological grade. Protein expression analysis revealed that the CF33, CYPp and CYPm cell lines expressed PDGFRα and that the CTB cell line expressed VEGFR-2, whereas none of the established cell lines expressed PDGFRβ or CD117 (Fig 2) . These data were confirmed by immunocytochemistry performed on CMC cell lines (Fig 3) . In the in vitro test, toceranib phosphate was able to slightly inhibit cell proliferation in the CTB cell line at 600nM (P=0.04) after 24 hours and at 1.5mM after 24 and 48 hours of treatment (Fig 4a) . In the CYPm cell line, inhibition was found only at 1.5mM after 48 hours (Fig  4b) . As shown in Fig 4c, the Penny cell line, which was used as a control, responded to toceranib phosphate in a range of 150-600nM corresponding to the IC50 at 12, 24 and 48 hours.
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Discussion
CMTs are one of the most common neoplasia in female entire dogs. Many recent efforts have been made to increase the knowledge of the pathogenesis of CMTs and to identify new histological biomarkers for prognosis and specific therapy. Toceranib phosphate is currently used to treat canine mast cell tumours, 21 32-34 but only one study evaluated the efficacy of this drug in CMTs, 22 where four of the five examined CMTs obtained a biological response to therapy (two partial response and two stable disease); however, no data about TKRs expression in these patients are available.
The present study evaluated the expression of PDGFRα, PDGFRβ, VEGFR-2 and CD117 in a large cohort of CMTs to compare their expression to histological features and to identify suitable biomarkers for specific therapy. Considering the importance of these TKRs in the microenvironment of human breast cancer, 18 35-38 their expression in epithelial and stromal cells was evaluated separately. The results of this study demonstrated the lack of PDGFRα and PDGFRβ expressions in simple carcinomas compared with mixed/complex carcinomas. None of the normal mammary glands expressed PDGFRs, but 54.5 per cent of benign tumours were positive. On the basis of these results, it could be assumed that these receptors play different roles in benign and malignant tumours; thus, their possible role in the progression from the benign to malignant phenotype in CMTs needs to be investigated. In particular, considering simple carcinomas, PDGFRα and β are not expressed at the epithelial level in 26/42 and 30/42 (61.9 per cent and 71.4 per cent) of the cases, respectively. These results partially correspond to human breast cancer, where PDGFRβ is expressed exclusively in stromal cells in 35 per cent of cases; it represents a negative prognostic factor and is usually correlated with the triple negative phenotype, [39] [40] [41] whereas PDG-FRα is expressed in 39.2 per cent of breast cancer cases in both epithelial and stromal cells. 42 On the basis of the varying results obtained, it was hypothesised that different hormonal responses and regulation in the two species should influence the expression of PDGFRs in canine simple carcinoma but further investigations are needed. 43 Similar to other authors, VEGFR-2 expression was slightly increased in malignant forms (55 per cent of cases), but in this study no statistical correlation was found with histological grade (P>0.05). In veterinary literature, several papers investigated VEGFR2 expression in CMTs especially in relation to microvessel density, VEGF-A expression and clinical follow-up, but so far a full agreement between the authors has not been reached. 15 44-46 The results obtained in this work are mainly in contrast to those of Restucci and others 44 that reported a number of positive endothelial and neoplastic cells, higher in malignant tumours compared with the benign type. This disagreement should be explained by the different methodological approach used to evaluate the positivity of VEGFR-2. In this study, the authors evaluated separately the expression of VEGFR-2 in neoplastic and in stromal cells in each sample, while Restucci and others evaluated the total positivity of VEGFR-2 in neoplastic and endothelial cells. Moreover, the data are similar to those obtained in human beings, where the IHC expression of VEGFR-2 ranged between 63.0 per cent and 69.0 per cent 47 and was generally related to an aggressive phenotype and a poor prognosis. 48 Finally, the data demonstrated that CD117 is expressed in 38.5 per cent of the malignant samples without a statistical association with histotype: these data are in contrast with Brunetti and others 16 that demonstrated an expression of 66.6 per cent of the malignant cases with a statistical association between CD117 labelling pattern and histological type and Ki67 index. This disagreement may be linked to the different number of cases enrolled and to the use of a previous classification. 49 Therefore, further investigations are necessary to clarify the role of CD117 in this tumour. Nevertheless, these data are in agreement with the human literature, where high-grade carcinomas do not express CD117. 50 51 WB analysis confirmed the antibody specificity and showed that these receptors are poorly expressed in carcinoma cell lines analysed. Finally, the in vitro assay suggested that the response to drugs is strictly dependent on the presence of specific TKRs on the cellular membrane surface. The results of the present study demonstrated the lack of PDGFRα and PDGFRβ expressions in simple carcinomas and, on the basis of preliminary results, we can assume that the biological effect of toceranib phosphate on CMCs is strictly correlated with the specific TKRs cellular expressions. These data should be considered before a specific medical treatment is initiated, although further clinical studies in this direction are needed.
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